Generics 14

Originals

Biosimilars

Medical devices

Nutraceuticals

Filters

Ruxolitinib manufacturers

14 products found

Filters

14 products found

ruxolitinib

Tablets, extended release (ER) 10 mg, 20 mg, 30 mg, 40 mg, 50 mg

Dossier type
EU CTD
Dossier status
Ready to file
Country of origin
European Union
GMP approvals
EU GMP
Manufacturer #21467

Manufacturer usually replies in 4 days

ruxolitinib

Tablets 5 mg, 10 mg, 15 mg, 20 mg

Dossier type
EU CTD
Dossier status
Under development
Country of origin
European Union
GMP approvals
EU GMP
Comments
Ref: Jakavi®
Manufacturer #252

Manufacturer usually replies in 2 days

ruxolitinib

Tablets, immediate release (IR) 5 mg, 10 mg, 15 mg, 20 mg

Dossier type
EU CTD
Dossier status
Under development
Country of origin
European Union
GMP approvals
EU GMP
Manufacturer #21467

Manufacturer usually replies in 4 days

ruxolitinib

Cream 1.50 %

Dossier type
EU CTD
Dossier status
Under development
Country of origin
European Union
GMP approvals
EU GMP
Manufacturer #21467

Manufacturer usually replies in 4 days

ruxolitinib

Tablets 5 mg, 10 mg, 15 mg, 20 mg, 25 mg

Dossier type
EU CTD
Dossier status
Under development
Country of origin
European Union
GMP approvals
EU GMP
Manufacturer #11907
A pharmaceutical manufacturer based in the EU that is active in 40+ countries selling its products for 20+ years. Key production lines include Rx, OTC, medical devices, and cosmetics. The company's production lines are EU GMP-compliant. The company owns branches in the EU, North America, and Africa.

Manufacturer usually replies in 8 days

ruxolitinib

Tablets 5 mg, 10 mg, 15 mg, 20 mg

Dossier type
EU CTD
Dossier status
Under development
Country of origin
European Union
GMP approvals
EU GMP
Manufacturer #614
A pharmaceutical manufacturer based in Europe selling its products in Europe and worldwide for 10+ years. Main dosage forms include injectable and oral dosage forms. The company's production lines are EU GMP-compliant. The main therapeutic area is oncology.

Manufacturer usually replies in 7 days

ruxolitinib

Tablets, film coated 5 mg, 10 mg, 15 mg, 20 mg

Dossier type
EU CTD
Dossier status
Under development
Country of origin
European Union
GMP approvals
EU GMP
Unavailable markets
Vietnam
Available for
Licensing with supply
Comments
INot open to MENA for this produc. ndication: Myelofibrosis; Status: Q1 2025 Under Development
Manufacturer #385
A pharmaceutical manufacturer based in the EU that has been active in 60+ countries selling its products in Europe, North America, LATAM, MENA, Africa, and Asia for 60+ years. Key production lines are Rx and nutraceuticals. The company's production lines are EU GMP-compliant.

Manufacturer usually replies in 11 days

ruxolitinib

Tablets 5 mg, 10 mg, 15 mg, 20 mg

Dossier type
EU CTD
Dossier status
Under development
Country of origin
European Union
GMP approvals
EU GMP
Comments
Dossier availability date: Q2 2024
Manufacturer #17047
A pharmaceutical manufacturer based in the EU that sells its products in Europe, the Middle East, CIS, LATAM, and Asia. Key production lines are pharmaceuticals, bio and nanopharmaceuticals, medical devices, and nutraceuticals. The main therapeutic area is oncology.

Manufacturer usually replies in 10 days

ruxolitinib

Tablets 5 mg, 10 mg, 15 mg, 20 mg

Dossier type
EU CTD
Dossier status
Under development
Country of origin
European Union
GMP approvals
EU GMP
Manufacturer #260
Pharmaceutical manufacturer operating in the EU for 50+ years. Activities include scientific development, manufacturing, out-licensing, marketing, and distribution of high-quality generic medicines. The company owns several production facilities that all comply with EU GMP requirements. Key dosage forms include conventional solids, cytostatic injectables, and cytostatic orals. The company holds an in-house R&D and Intellectual property business unit, as well as a regulatory affairs team that prepares CTD dossiers and maintains direct contact with regulatory agencies worldwide. The portfolio includes more than three thousand MA sets approved in the EU while hundreds of MA are in progress. Key therapy lines are cardiovascular, CNS, diabetes, immunology, oncology, and more. The company is active in nearly 100 countries worldwide, selling its products in Africa, Asia, Australia, Europe, LATAM, and the Middle East.

Manufacturer usually replies in 12 days

ruxolitinib

Tablets 5 mg, 10 mg , 15 mg, 20 mg

Dossier type
EU CTD
Dossier status
Under development
Country of origin
Iceland
GMP approvals
EU GMP
Manufacturer #28915

Manufacturer usually replies in 16 days

ruxolitinib

Oral solution 2.5 mg/ml

Dossier type
EU CTD
Dossier status
Under development
Country of origin
European Union
GMP approvals
EU GMP
Manufacturer #31060

Manufacturer usually replies in nan days

ruxolitinib

Tablets 5 mg, 10 mg, 15 mg, 20 mg, 25 mg

Dossier type
CTD
Dossier status
Under development
Country of origin
Turkey
GMP approvals
EU GMP
Manufacturer #2722
It originally entered the pharmaceutical industry in 1987, when it introduced blood derivative products to Europe and became the exclusive distributor for prominent European brands. Oncology, hematology, dermatology, radiology, rheumatology, immunology, and OTC products are the seven main therapeutic fields.

Manufacturer usually replies in 6 days

ruxolitinib

Tablets, immediate release (IR) 5 mg, 10 mg, 15 mg, 20 mg, 25 mg

Dossier type
EU CTD
Dossier status
Ready to file
Country of origin
India
GMP approvals
FDA, EU GMP, WHO, MHRA
Manufacturer #16394

Manufacturer usually replies in 13 days

ruxolitinib

Tablets, immediate release (IR) 5 mg, 10 mg, 15 mg, 20 mg, 25 mg

Dossier type
US CTD
Dossier status
Ready to file
Country of origin
India
GMP approvals
FDA, Canada
Manufacturer #16394

Manufacturer usually replies in 13 days

RUXOLITINIB manufacturer

Ruxolitinib, also known by the brand names Jakafi and Jakavi, is a drug used to treat intermediate and high-risk myelofibrosis, a type of myeloproliferative disorder that affects the bone marrow, polycythemia vera (PCV) when hydroxyurea treatment has failed or is intolerable, and steroid-refractory acute graft-versus-host disease. Incyte Corp developed and sold it in the United States under the brand name Jakafi, and Novartis developed and marketed it in the rest of the world under the brand name Jakavi. It's unclear whether Jakafi is safe and effective for children under the age of 12. Warnings: Follow all Instructions on your medicine package and label. It is wise to tell your healthcare providers about all your medical allergies, illnesses, and all medicines you use. Before taking RUXOLITINIB: You should not use This medical drug if you are allergic to it This drug may also be used for purposes that may not have been listed in this medication guide. Buyers are advised that online sellers may attempt to market fraudulent versions of the generic drug, whereas Pipeline Pharma, through its pre-auditing and quality control procedures ensures that only verified rosiglitazone manufacturers and wholesalers enter our online marketplace, offering you a risk-free B2B pharmaceutical sales platform.

How does RUXOLITINIB work?

The usage of this pharmaceutical substance: Read the Guide and, if available, the Patient Information Leaflet that will be provided by your pharmacist before you start taking RUXOLITINIB. If you have any questions related to this medical remedy, ask your pharmacist or doctor. The medicine works by blocking JAK1 and JAK2 signaling in cytokines (small cell-signaling protein molecules) and growth factor receptors. The medication inhibits malignant cell proliferation and regulates cytokines that contribute to a hypermetabolic condition. This medicine was first licensed by the FDA in 2011 for the treatment of adult patients with myelofibrosis, and then by the European Medicines Agency in 2012. Ruxolitinib was licensed in 2014 for the treatment of polycythemia vera in adults who do not respond to or tolerate hydroxyurea, and in 2019, it was approved for the treatment of steroid-refractory acute graft-versus-host disease in adults and children. Ruxolitinib is available as a tablet that must be swallowed. It's commonly taken twice a day, with or without food. Every day, take ruxolitinib at the same time. Take this pharmaceutical product by mouth without or with food as instructed by your doctor, usually twice daily. If you are unable to swallow the whole tablets, ask your health care provider about other ways to take this medical remedy. The dosage is based on your laboratory test results, medical condition, response to treatment, and other medicines that you may be taking. Be sure to let your pharmacist and doctor know about all the products you use (including nonprescription drugs, prescription drugs, and herbal products). It is wise to avoid drinking grapefruit juice or eating grapefruit while using this medicine unless your pharmacist or doctor says you may do so safely. Grapefruit can improve the chance of side effects with this prescribed drug. Ask your pharmacist or doctor for more details.

The Wholesale Price of RUXOLITINIB?

It is obtainable in generic and brand versions. It is not covered by most Medicare and insurance plans, but pharmacy coupons can help balance the price. In the US, The cost for a Ruxolitinib oral tablet 5 mg costs roughly $15,413 for a supply of 60 tablets. Prices may vary on the pharmacy you visit.

Sourcing the RUXOLITINIB Manufacturers and Suppliers

If you are looking to find RUXOLITINIB manufacturers and RUXOLITINIB suppliers, locate them quickly using Pipelinepharma's online marketplace. With this convenient B2B platform, you can order types of medications and quantities you require from companies that have passed our stringent vetting and quality control procedures. Being a global B2B pharmaceutical online marketplace, Pipelinepharma is structured to simplify pharmaceutical deals by providing you with an intuitive interface that is easy to engage with. The selection of RUXOLITINIB suppliers offerings can be narrowed down with the use of filters and easily weighed against one another according to medication prices and commercial terms. The advanced filters help you filter out the countries for this substance manufacturer and these substance suppliers that you are looking for. These also enable you to check the dossier status of this medicine, and the GMP approvals of the different variants of RUXOLITINIB. Also, each manufacturer or supplier product description contains essential information about this substance including clinical data, stability zones, countries where RUXOLITINIB is already registered in. Manufacturers also have special, and delivery terms.

Establishing commercial ties

If you are a pharmaceutical licensing company or a distributor you can enter into deals or negotiations over these medicine offers with manufacturing companies after completing the free registration process and joining our online marketplace. This helps to ensure that you conclude the pharmaceutical deal at a reasonable cost and achieve the best cost/benefit ratio for your company while bypassing lengthy sourcing, negotiation, and ordering process. Once you have finalized a deal, you can look forward to a long-lasting business relationship with the manufacturers or suppliers. This way, the marketplace allows you as a distributor to skip the process of shortlisting product manufacturers every time you are looking for in-licensing or distribution deals.

Quality Assurance

To keep up to the quality standards other than Good Manufacturing Practice approvals that this medicine manufacturers list has, we qualify their companies before they are onboarded on the platform. This allows us to screen RUXOLITINIB manufacturers for the quality of the pharmaceutical products’ dossiers and protect against the risk of possible malpractices.